Eledon Pharmaceuticals Inc ELDN

US Biotechnology

$3.38 ▼ -0.88% ($-0.03)

⬆️ Above Yest. High 🗓️ Earnings Next Week

Open $3.41

Prev Close $3.41

Day Range $3.26 – $3.49

52W Range $1.35 – $4.60

Market Cap $260.89M

Beta 0.99

EPS (TTM) $-0.83

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2014-09-17
Shares Out.	77,190,000
Website	eledon.com/ ↗
Phone	13025814070
Employees	33
Net Income	-$39.0M
Total Assets	$146.7M
Total Liabilities	$46.2M
Equity	$44.8M

About Eledon Pharmaceuticals Inc

Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.

Eledon Pharmaceuticals Inc is a publicly traded company under the ticker symbol ELDN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.